TAY R2
Alternative Names: TAY-R2Latest Information Update: 04 Aug 2023
At a glance
- Originator Tay Therapeutics
- Class Antifibrotics; Skin disorder therapies; Small molecules
- Mechanism of Action Gene expression modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Research Cystic fibrosis; Epidermolysis bullosa
Most Recent Events
- 20 Jul 2023 TAY R2 is available for licensing as of 20 Jul 2023. https://taytherapeutics.com/pipeline/?loc=partnerships
- 20 Jul 2023 TAY therapeutics plans a phase IIa trial (TAY therapeutics pipeline, July 2023)
- 17 Jul 2023 Early research in Cystic fibrosis in UK, prior to July 2023(Topical) (TAY therapeutics pipeline, July 2023)